Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies
NCT06993025
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Biliary Tract Cancer
Interventions
DRUG:
Ivonescimab+chemotherapy
Sponsor
Tianjin Medical University Cancer Institute and Hospital